PROSTASCINT effective in guiding targeted prostate cancer treatment
November 4th, 2009 Posted in prostate cancerAccording to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois,
PROSTASCINT - capromab pendetide - was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival.